News

Growth Is Priced Out Of Novo Nordisk
Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...
ESSENCE Phase 3 Trial Of Semaglutide Showed Significant Improvements At 72 Weeks In Adults With MASH, Published In NEJM
Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion ...
HealthShots on MSN3d
Mounjaro vs Ozempic: What’s the difference between these 2 diabetes and weight loss drugs?
Obesity is a global pandemic. According to the World Health Organization (WHO), adult obesity in the world more than doubled ...
pharmaphorum2d
AstraZeneca improves diabetes pen to maintain its market share
The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug ... device that requires no titration and is approved for ...
BlackRock Greater Europe Investment Trust Plc - Half-year Report
Chairman's Statement Overview The Company's Net Asset Value (NAV) underperformed the reference index (the FTSE World Europe ex UK Index) over the six months under review, ending the period only ...
pharmaphorum3d
Wegovy finally reaches the UK, in 'limited' quantities
Demand for Wegovy (semaglutide) has been rocketing since ... a body mass index of 35 or more and a concomitant illness like diabetes, or a BMI of 30 or more and a referral to NHS weight-loss ...